0000000000385945

AUTHOR

Satoru Kakizaki

showing 2 related works from this author

Advancing the global public health agenda for NAFLD: a consensus statement

2021

Digital

medicine.medical_specialtyCivil societyDelphi methodMEDLINENashMULTIDISCIPLINARY APPROACHDiseaseLATIN-AMERICAN ASSOCIATIONMultidisciplinary approachQUALITY-OF-LIFENon-alcoholic Fatty Liver DiseaseEpidemiologyMedicineHumansHumans; Non-alcoholic Fatty Liver DiseasePOSITION STATEMENTBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.FATTY LIVER-DISEASEBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Hepatologybusiness.industryPublic healthGastroenterologyALCOHOLIC STEATOHEPATITISNONINVASIVE DIAGNOSISmedicine.diseaseObesityCARDIOVASCULAR-DISEASEPRACTICE GUIDELINESFamily medicinePRACTICAL APPROACHHuman medicinebusiness
researchProduct

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

2022

Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not …

Cancer ResearchSettore MED/12 - GastroenterologiaLenvatinib.OncologyAdvanced HCCAtezolizumab plus bevacizumabFirst-line therapyGeneral Medicine
researchProduct